Brits Lead Charge In Global Battle Against Antimicrobial Resistant Superbugs

Tackling an unmet need is a common focus for pharmaceutical companies when choosing the therapeutic areas they will concentrate on – but it is often not enough. Pharma business executives have also got to be able to see a clear route to returns on their investments. While no one doubts the huge medical challenge antimicrobial resistance (AMR) poses, how to incentivize companies to work on solutions is proving to be more difficult. During BIO 2018, held in Boston, June 4-7, researchers from the UK discussed what efforts were being made to devise incentivization models.